Ovarian Cancer section

Ovarian Cancer News & Features

Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer

Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer

Rubraca (rucaparib) received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with previously treated BRCA-positive ovarian cancer.

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

Including a PI3-Kinase Inhibitor with an PARP Inhibitor Improves Tumor Shrinkage in Patients with Resistant Ovarian Cancer

Tumor shrinkage was seen in plantinum-resistant ovarian tumors when treated with a combination of a PARP inhibitor and an alpha-specific PI3-kinase inhibitor.

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

Concurrent, Maintenance Therapy With Cediranib Maintains QOL in Ovarian Cancer

Quality of life was maintained in patients with ovarian cancer who received chemotherapy with concurrent cediranib then cediranib alone as maintenance therapy.

12 More Genetic Variants Found to Increase Risk for Ovarian Cancer

12 More Genetic Variants Found to Increase Risk for Ovarian Cancer

A team of international researchers identified 12 new genetic variants that increase a woman's risk of developing ovarian cancer.

Quarterly Testing for Biomarker Improves Detection of Early-Stage Ovarian Cancer in High-Risk Women

Quarterly Testing for Biomarker Improves Detection of Early-Stage Ovarian Cancer in High-Risk Women

A protocol of testing of CA125 levels quarterly with subsequent transvaginal ultrasound examination increased detection of early-stage ovarian cancer in women at high-risk for the disease.

Priority Symptoms Identified in Recurrent Ovarian Cancer

Priority Symptoms Identified in Recurrent Ovarian Cancer

There are 18 core priority symptoms that should be routinely assessed in patients with recurrent ovarian cancer to provide higher quality of care.

Web-based Symptom Management Improves Symptom Controllability in Ovarian Cancer

Web-based Symptom Management Improves Symptom Controllability in Ovarian Cancer

Nurse-guided and self-directed web-based symptom management interventions (WRITE Symptoms) improved symptom controllability among women with recurrent ovarian cancer.

Some Quality Metrics Inconsistent With Long-Term Clinical Outcomes Goals

Some Quality Metrics Inconsistent With Long-Term Clinical Outcomes Goals

Study finds that instituting a health system-wide quality metric, such as postoperative hospital readmission rate, may be inconsistent with long-term clinical outcomes goals.

Ovarian Cancer: Distinct Clusters of Chemotherapy Nonresponders Identified

Ovarian Cancer: Distinct Clusters of Chemotherapy Nonresponders Identified

A study that integrated genomic and clinical data identified 3 distinct clusters of patients with serous epithelial ovarian cancer who do not respond to chemotherapy.

Recovery Program After Laparotomy More Cost-Effective Than Usual Care

Recovery Program After Laparotomy More Cost-Effective Than Usual Care

An enhanced recovery program is more cost-effective than usual care in patients undergoing primary cytoreductive surgery for ovarian cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs